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Abstract: There is always a need for alternative and efficient methods of drug delivery. The nasal cavity can be 
considered as a non-invasive and efficient route of administration. It has been used for local, systemic, brain targeting, 
and vaccination delivery. Although many intranasal products are currently available on the market, the majority is used 
for local delivery with fewer products available for the other targets. As nanotechnology utilization in drug delivery has 
rapidly spread out, the nasal delivery has become attractive as a promising approach. Nanoparticulate systems facilitate 
drug transportation across the mucosal barrier, protect the drug from nasal enzyme degradation, enhance the delivery of 
vaccines to the lymphoid tissue of the nasal cavity with an adjuvant activity, and offer a way for peptide delivery into the 
brain and the systemic circulation, in addition to their potential for brain tumor treatment. This review article aims at 
discussing the potential benefit of the intranasal nanoparticulate systems, including nanosuspensions, lipid and 
surfactant, and polymer-based nanoparticles as regards productive intranasal delivery. The aim of this review is to focus 
on the topicalities of nanotechnology applications for intranasal delivery of local, systemic, brain, and vaccination 
purposes during the last decade, referring to the factors affecting delivery, regulatory aspects, and patient expectations. 
This review further identifies the benefits of applying the Quality by Design approaches (QbD) in product development. 
According to the reported studies on nanotechnology-based intranasal delivery, potential attention has been focused on 
brain targeting and vaccine delivery with promising outcomes. Despite the significant research effort in this field, 
nanoparticle-based products for intranasal delivery are not available. Thus, further efforts are required to promote the 
introduction of intranasal nanoparticulate products that can meet the requirements of regulatory affairs with high patient 
acceptance. 
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1. INTRODUCTION  
Clear evidence of the nasal cavity as an effective route of administration has attracted research groups to concentrate on 
exploiting this region as an alternative means for systemic and brain delivery of drugs and vaccines to overcome the 
inconvenience of already available routes. 
Over the past decades, nanotechnology has gained an advanced position in drug delivery approaches. A nanoparticulate system 
holds a great value over the manipulative characteristics of the applied therapeutics, such as solubility, permeability, and half-
life. These features allow the extended use of nanoparticulates for cancer targeting and controlled release purposes. Many 
parenteral, oral, and topical nanoparticulate therapeutics are available on the market and clinical trial stages [1–8].  
The term nanotechnology is also widely used and defined as the control and manipulation of matter at the nano-scale (10-100 
nm). However, the particles within the size range of 1-1000 nm are considered as nanoparticles in practice. Nanoparticles are 
regarded as special due to the fact that particles on the nanometer scale have unique optical, electronic, and structural/functional 
properties distinctive from the normal size. Moreover, higher permeability, a large surface to volume ratio, and higher 
mucoadhesion can be achieved as a consequence of nanosizing [9–13]. 
Nanosystems form a special group regarding their regulatory acceptance. Related guidelines and relevant chapters of the 
European Medicines Agency (EMA) and the Food and Drug Administration (FDA) must be applied during all manufacturing 
stages from material selection and formulation to the final production. Furthermore, the FDA has emphasized the application of 
the Quality by Design (QbD) methodology, which can be especially useful for novel, high risk dosage forms and administration 
routes. The adoption of the International Council on Harmonization (ICH) guidelines for pharmaceutical development-Q8, risk 
management-Q9 and quality system-Q10 provides great potential for careful planning during the formulation and development 
even in the early phase of the research [14–20]. 
A high number of successful applications of nanoparticulate systems in drug delivery motivated to apply this technology in the 
case of the intranasal route; in order to improve drug delivery and to overcome the limits of this administration route. A 
combination of novel nanotechnology developments together with increased knowledge on intranasal delivery can efficiently 
lead to substantial advances in drug delivery with enhanced bioavailability and patient acceptance.  
2. NASAL CAVITY 
2.1 Nasal Anatomy  
As known from anatomy studies, the human nasal cavity (Fig 1) is composed of two symmetrical chambers (nostrils) separated 
by the median septum, the area inside each chamber is divided into the nasal vestibule area and the main nasal cavity containing 
the respiratory and olfactory regions. The total surface area and volume of the nasal cavity are 150 cm2 and 15 ml, respectively 
[21,22]. 
The nasal respiratory area is the largest part of the nasal cavity, it is confined between the septal and lateral walls and it contains 
the superior, middle, and inferior turbinates forming the slit-like area that is responsible for the humidification and temperature 
regulation of the inspired air [23]. 
The uppermost region of the nasal cavity is the olfactory region, which is responsible for the sense of smell. This area 
comprises 10% of the total intranasal cavity and the olfactory information is sent from the olfactory bulb via the olfactory 
neuron into the piriform cortex, amygdala, and entorhinal cortex; where this can promote direct brain transport [24,25]. 
The cell lining type varies along the nasal cavity; the vestibules are covered by non-ciliated squamous and transitional 
epithelium with poor blood perfusion, whereas the respiratory region is covered by epithelium consisting of ciliated, 
pseudostratified, and columnar epithelium cells with a rich blood supply from the underlying lamina propria. The presence of 
microvilli along with columnar cells intensifies the surface area available for drug absorption, as each cell covered with 300 
microvilli, and their fine projections (cilia) are fundamental to mucus transport into the nasopharynx. The topographical and 
physiological features of the respiratory region are responsible for being the main region for permeation. Similar to the 
respiratory area, the olfactory region is covered by pseudostratified epithelium with a specialized refractory receptor for smell 
perception. Prior to transfer, the olfactory component must be dissolved in the serous fluid that is produced and secreted by 
Bowman's gland [26–29]. 
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Besides the significance of the respiratory region for systemic absorption, it plays a crucial role in direct drug delivery into the 
brain through the trigeminal region. The olfactory and trigeminal structures act as the only available apertures of the central 
nervous system (CNS) entry [30]. 
The anatomical aspect plays a crucial role in nasal delivery. To get the benefit of the high surface area of the nasal cavity and 
its consequences on higher absorption, the formulation must be spread over a large mucosal area. The place of distribution 
inside the cavity is essential for the activity; for example, for local delivery, systemic delivery, and vaccines, broad distribution 
is required whilst in brain targeting the drug must be delivered into the upper parts of the nose containing the olfactory region in 
addition to covering the trigeminal nerve, which may have a contribution in targeting. Such factors must be considered in 
selecting the dosage form and designing the delivery devices to ensure the proposed deposition and coverage of the formulation 
to get the intended response [31,32]. 
 
Fig. (1). Anatomical structure of the human nasal cavity. 
2.2 Nasal Cavity as Drug Route of Administration  
The distinction of the intranasal route is ascribed mainly to the anatomical and physiological characteristics of the nasal cavity. 
The nasal cavity offers a number of advantages, such as: avoiding first-pass metabolism, high surface area, high permeation, 
high vascularization, and having a nose to brain direct pathway as well as circumventing the blood brain barrier. Thus, the nasal 
route has the potential for the delivery of drugs that suffer from extensive first-pass metabolism, poor solubility, and 
degradation in the gastrointestinal tract. It is also an attractive site for vaccine and peptide delivery that have been parenterally 
administered so far. The intranasal route is a non-invasive, non-sterile, and easily administered method that can enhance 
patients' compliance [33–39]. 
On the other hand, many limitations could adversely affect nasal delivery, these include: mucociliary clearance, restricted 
volume of nasal administration (max. 200 ul), presence of enzymes and efflux transporters, pathological and environmental 
factors that affect intranasal blood supply. Moreover, the narrow nasal valve represents a potential obstacle to an efficient drug 
delivery [40–43]. 
2.3 Emerging Intranasal Application from Local to Systemic, Brain, and Vaccine Delivery 
The intranasal delivery of drugs has been initially utilized for the local treatment of topical conditions. Various marketed drugs 
have been used to treat congestion, nasal allergies, infections, and nasal polyps. Decongestants, steroids, and antihistamines are 
the most common drugs that are nasally applied for their local action [44–48]. 
As a consequence of the previously mentioned advantages, the nasal cavity has evolved from local administration into a route 
for systemic, brain targeting, and vaccine delivery. This extension has opened up the possibilities for all drug delivery purposes, 
including cancer treatment [49–53]. 
Intranasal products with systemic effects are commercially available for certain drugs such as zolmitriptan, sumatriptan, 
ergotamine, butorphanol tartrate, and fentanyl as well as peptides such as calcitonin, desmopressin, buserelin, and nafarelin 
[54–61]. Other drugs have been nasally introduced for the treatment of urgent conditions such as migraine, seizures, opioid 
overdose, and pain breakthrough in cancer [62–67]. 
Maximum 2% of drugs are capable of reaching the brain after systemic administration due to the presence of the protective 
brain capillary endothelium. The exploitation of the intranasal route to target the CNS is an attractive approach to circumvent 
the blood brain barrier (BBB) and deliver the drug directly through the cribriform plate, olfactory and trigeminal regions. 
Alzheimer’s disease, depression, migraine, schizophrenia, HIV consequences, and multiple sclerosis are all CNS diseases that 
systemic administration has failed to treat. The availability of an effective delivery rather than the drugs was the missing part 
for achieving considerable therapeutic outcomes [68–70].  
The intranasal cavity offers easy administration for vaccines, inducing both mucosal and systemic immunity. The importance of 
this site has evolved from the nature of infections itself since the majority of viral and bacterial infections start from the 
mucosal tissues. Both innate and adaptive immune responses can be directly initiated after the delivery of the antigen via nasal-
associated lymphoid tissues (NALT) through the distinctive M cells into the antigen sampling cells, dendritic cells, B-cells, and 
T-cells, being responsible for the humoral immune responses mediated by secretory IgA antibodies [71–74]. The 
pharmaceutical aspects of intranasal vaccination have been thoroughly discussed by Sharma et al. [75]. 
3. NANOTECHNOLOGY AS A FURTHER ASPECT OF THE INTRANASAL DELIVERY OF DRUGS 
3.1 Rationale for using Nanotechnology for Intranasal Delivery 
Within the last decades, tremendous efforts have focused on intranasal delivery and its potential for different applications 
beyond its local importance; to achieve systemic delivery and brain targeting in addition to mucosal and systemic vaccination.  
Hypothetically, the ideal route is available. Nevertheless, many limitations can hamper its efficiency. The combination of 
nanotechnology as the drug preparation method and intranasal delivery as the route is supposed to provide an effective delivery 
system. Nanotechnology offers the criteria for achieving high solubility and dissolution rates, which are the key factors for drug 
absorption and activity. Furthermore, this technology can protect the drugs from nasal enzyme activity, counteract the 
mucociliary action to increase contact time and promote permeation. Table 1 lists the nanotechnology effects on the major nasal 
delivery limitations and Table 2 identifies the rationale for using the nasal passage as a route for administration and 
nanoparticles as a technology for various targets. Many risks can also be increased, such as toxicity or even the inhalation of the 
nano-scale particles. Thus the identification of the risks associated with the intranasal delivery of nanoparticles must be 
cautiously evaluated [76–78] 
Table 1. Nanotechnology solutions for intranasal delivery limitations. 
 
Limitation Nanotechnology effects Refs  
Poor drug solubility  High ratio of surface area to volume 
Interactions between the groups of the polymer and drug molecule, such as 
electrostatic, and H-bonding 
Production of a microenvironment with special lower polarity inside the 
nanoparticles than in the aqueous bulk phase  
[79–
83] 
Mucociliary clearance and short 
residence time 
Localization of the formulation for a longer time 
Enhancement of contact time inside the nasal cavity  
[84–
86] 
Poor penetration for large and 
hydrophilic molecules  
Ability to open up tight junctions 
Possibility of high endocytosis  
Ability to change mucosal membrane properties  
[87,88] 
Enzymatic activity  Encapsulation of liable molecules [89] 
P-glycoprotein efflux transporter  Efficiency for bypassing and inhibition of P-glycoprotein [90,91] 
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Table 2. Rationale for the use of the nasal route and nanoparticulate systems with various targets. 
 
Target  Rationale for nasal 
delivery 
Rationale for using nanoparticulate systems 
Local Rapid onset of action 
Minimum effective dose 
Minimum side effects  
Enhancement of contact time with mucosa  
 
Systemic  Ease of administration  
Rapid onset of action 
Avoidance of first-pass 
metabolism  
Avoidance of gastric 
deterioration and enzymatic 
degradation 
Delivery of peptide, proteins, and high molecular weight therapeutics   
High systemic absorption 
Brain Circumvention of the blood 
brain barrier  
Noninvasive application of 
anti-tumor agents 
Drug targeting  
Delivery of peptide, proteins, and high molecular weight therapeutics 
Vaccination 
 
Noninvasive  
Induction of mucosal and 
systemic immunity 
Adjuvant activity  
 
3.2 Pharmaceutical Factors of the Influence of Nanoparticles on Intranasal Delivery  
The pharmacokinetics and bioavailability of the applied drug (vaccine) are ruled by different factors related to the properties of 
both the active pharmaceutical agent (API) and the formulations. These factors determine the mechanism of absorption through 
the nasal mucosa [92]. 
Nanomaterials possess distinctive physicochemical properties compared to their conventional counterparts, and these properties 
provide nanoparticles with beneficial characteristics. The physicochemical characteristics of nanoparticles which most 
influence their administration through the nasal route include size, shape, chemical composition, physiochemical stability, 
crystal structure/polymorphism, surface area, surface charge, and surface energy in addition to drug loading and drug 
entrapment efficiency. 
Particle size is a critical evaluation parameter to assess the desired properties of nanoparticles due to its consequences on 
surface area and viscosity, and thus drug dissolution, release, absorption, and stability [93]. Due to their small size, 
nanoparticles are usually used as a drug carrier via passive transport, active transport, and endocytosis [94,95]. However, the 
mechanism by which nanoparticles enhance drug transport is not fully described. Some studies considered that nanocarriers 
interact with the mucus layer and release the drug in the mucus or at the mucus–epithelial cell interface, while other studies 
implied that the drug-loaded nanoparticles themselves cross the mucosal barrier. Both cases involve the uptake of nanoparticles 
into the respiratory or olfactory epithelium and then drug payload diffused into the systemic circulation or to the CNS. Surface 
charge also plays an important role in the interactions of nanoparticles with biological systems. For example, positively charged 
nanoparticles have been designed to improve nasal adhesion with the nasal mucosa via the electrostatic interaction with the 
sialic groups of mucin [96]. Furthermore, it has also been observed that the surface charge of nanoparticles alters blood-brain 
barrier integrity and transmembrane permeability [95]. 
There is no clear trend found which is concerned with the influence of nanoparticle size on drug uptake into the tissue [97]. 
Therefore, the effect of these important factors on drug permeability has been discussed in many studies. Some authors studied 
the in vitro transport across nasal epithelium, ex vivo across nasal mucosa or in vivo with animal models. Brooking et al [98] 
studied the transport of 12’1-radiolabelled latex nanoparticles by using a range of particle sizes and surface coatings across rat 
nasal mucosa. Among 20, 100, 500, and 1000 nm of non-modified nanoparticles, the 20 nm sized particles showed the highest 
extent in the systemic circulation. The 20 nm sized nanoparticles showed 2-fold higher blood concentration than the 100 nm 
sized particles, while 500 and 1000 nm sized particles showed similar lower levels of uptake; half of these seen for the 100 nm 
sized particles. The surface modification of 100 nm sized particles changed the surface charge. This change had a significant 
effect on the uptake of the particles into the systemic circulation. Coating the particles with poloxamine 908 (-14 mV zeta 
potential) resulted in a significant reduction in uptake compared with the uncoated particles (-49 mV zeta potential). However, 
coating of the polystyrene particles with Poly-I-lysine (PLL) (25 kDa) and PLL (I28 kDa) with zeta potentials +33 and +19 
mV, respectively, did not significantly change the levels of particles transported into the blood stream as compared to the 
uncoated particles despite these former particles had a positive surface charge. It is worth noting that these results contradicted 
what has been previously proved, namely that PLL is able to open the tight junction and increase the transport across the nasal 
membrane into the blood stream. It was expected that PLL-coated nanoparticles would give greater transport across the nasal 
membrane [99]. On the other hand, 100 nm chitosan modified particles resulted in a significant increase in the transport of 
particles into the blood stream due to its mucoadhesive effects and ability to open the tight junction. 
Gartziandia et al [100] studied the transport of polymeric and lipid-based nanoparticles with the same surface charge (-23 mV) 
across olfactory monolayers in rats. 100 nm sized nanostructured lipid carriers (NLCs) penetrated to a higher extent compared 
to the 220 poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Moreover, the positively charged chitosan-coated NLCs 
increased the transcellular transport by almost threefold compared to the uncoated NLCs. Mistry et al [101] studied the 
transport of different-sized fluorescent carboxylated polystyrene nanoparticles across excised porcine olfactory epithelium 
mounted in a vertical Franz Diffusion Cell. 20, 100, and 200 nm of the non-modified nanoparticles (surface charge -42 mV) 
were compared to Polysorbate 80-modified polystyrene nanoparticles (-21 mV) and chitosan-modified nanoparticles (+42 mV 
surface charge). Polysorbate 80-coated (PEGylated) particles penetrated deeper in the tissue compared to the uncoated and 
chitosan-coated nanoparticles. 
A study by Ahmad et al [102] discussed the effects of nanoemulsion (NE) particle size on the permanence of the NE within the 
nasal cavity. NEs with droplet size of 80, 200, 500, and 900 nm were compared. The NEs were prepared from 
Labrafac®WL1349/Labrafac® CC and Soluto®. The results showed that the smaller the droplet size, the higher permanence 
within the nasal mucosa. The study also confirmed the translocation of 100 nm in the nasal mucosa and along the trigeminal nerve 
to the olfactory bulb. However, large nanodroplets (900 nm) were not transported to the olfactory bulb. 
The shape of nanoparticles influences their stability, absorption, and cellular uptake. The spherical shape is the most stable 
thermodynamically. However, these effects are cross-linked with particle size and surface charge. Gratton et al [103] 
designed a series of particles with different sizes and shapes to study the interdependent effect of size  and shape on their 
internalization by human cervical carcinoma epithelial (HeLa) cells. Nanoparticles and microparticles were prepared by 
using particle replication with non-wetting templates method. The particles were made of cationic, cross-linked 
poly(ethylene glycol) hydrogels. Three series were produced as follows: cubic-shaped particles (2, 3, and 5 μm cube side 
length), cylindrical particles with identical heights but varying diameters (0.5, and 1 μm diameters), and cylindrical shaped  
nanoparticles (100, 150, 200 nm diameters). The results showed a strong dependence of cellular internalization on the  size 
and shape of the particles. 2 μm cubic particles showed a significant internalization by the most cells, whereas 3, and 5 μm 
showed insignificant internalization. The cylindrical nanoparticles showed the same level of internalization, which was 
higher than the 2 μm cubic particles. The cylindrical nanoparticles showed a very high degree of internalization. Moreover, 
it was found that 100 nm cylindrical particles were internalized to a lesser extent than the larger 150 nm cylindrical 
nanoparticles with the same ratio aspect. In another study, Chithrani et al [104] also used HeLa cells to investigate the 
intracellular uptake of spherical and rod-shaped gold nanoparticles. The results revealed that the uptake of rod-shaped 
nanoparticles was lower than that of their spherical counterpart. The difference in the surface chemistry between the two 
shapes could be one of the reasons for such uptake differences. However, the cellular uptake of rod-shaped structures with 
a lower aspect ratio (1:3) is greater than in the case of nanoparticles with a higher aspect ratio (1:5) although both of these 
rod-shaped gold nanoparticles were modified by cetyl trimethylammonium bromide.  
Shi et al [105] developed a model to figure out the basic mechanisms for the uptake and release of nanoparticles in animal 
cells. The authors reported that there is an optimal particle size as well as an optimal shape for the maximum rate of particle 
absorption and release. Other studies showed the relationship between cellular uptake and nanoparticle size, shape, and surface 
chemistry, and the mechanism of cellular uptake were reported in literature [106–108]. The parameters affecting the loading 
and entrapment efficiency must be controlled to achieve a desirable and controlled release profile concerning the total amount 
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of the released drug and the release kinetics. Accordingly, the amount of the loaded agent, the composition of the nanoparticle 
forming materials, the molecular weight of the constituents, the ratio of the active agent to the additives, concentration, and the 
type of the used stabilizing agents, and the manufacturing process parameters that can affect these properties must be 
investigated prior to preparation [109]. 
In addition to the pharmacokinetic properties, interaction with the mucosal tissue and the bioadhesive properties of the 
nanoparticles inside the nasal cavity are significant factors that can influence the delivery of the API. Mucus represents a 
challenge for drug delivery. The barrier properties of nasal mucus are related to the dense fiber network of mucin containing 
highly glycosylated (negatively charged) parts. Thereby, the way to increase interaction with mucus is by applying nanocarriers 
with a positive surface charge.  
Another strategy has been used to modify the interactions with mucus; a way to produce mucus penetrating nanoparticles is by 
PEGylated modification of nanoparticle surfaces [110,111]. Many studies have identified and discussed the effects of PEG on 
nanoparticle transport across the nasal mucosa. For example, PEG-modified polylactide-polyglycolide (PLGA) nanoparticles 
for the tetanus toxoid showed higher antibody levels following the intranasal delivery than those corresponding to PLA 
unmodified nanoparticles. Moreover, the fluorescence microscopy studies revealed that the PEG-PLA particles were able to 
cross the rat’s nasal epithelium to the brain [112]. Another study reported that PEGylated liposomes had shown greater uptake 
of risperidone into the brain in comparison to liposomes and cationic liposomes [113]. 
In conclusion, it is essential to characterize the nanomaterial properties and their interaction with the biological agent to 
produce successful nanoparticle systems and novel delivery. 
This review shows the most common nanoparticulate systems intended for intranasal application with recent literature studies. 
4. NANOPARTICULATE SYSTEMS FOR NASAL DELIVERY 
4.1 Intranasal Nanosuspensions/ Nanocrystals 
Nanosuspensions can enhance the dissolution rate and the saturation solubility of poorly water-soluble drugs. Nanosuspensions 
also offer the advantage of high drug loading capacity, and thus a possibility to introduce the required dose within the limited 
volume of the nasal cavity. Furthermore, small particles can penetrate the mucosal tissue more easily and are able to pass to the 
brain directly through the olfactory region, resulting in enhanced bioavailability [79,114]. 
The development of a nanosuspension for intranasal delivery for systemic purposes is demonstrated by Kürti et al [115]. In this 
study, a nanosuspension of meloxicam with 140 nm particle size has been prepared by co-milling with PVP-C30. The in vivo 
results showed the significant enhancement of the maximum plasma concentration (Cmax) and area under the curve (AUC) of 
the nasal meloxicam nanosuspension compared to the physical mixture (2.7-fold and 1.5-fold, respectively). The notable result 
was the tremendous differences in time required to reach Cmax (Tmax); 5 min for the intranasal nanosuspension compared to 90 
min for the oral administration with 1.6-fold higher Cmax. These results ensured the efficacy of intranasal delivery to achieve a 
rapid onset of action close to intravenous (IV) administration. Another example showed the importance of a lyophilized 
nanosuspension (nanocrystals) for brain targeting of resveratrol with deacetylated gellan gum as an in situ ionic sensitive 
gelling agent. Intranasal delivery showed both brain Cmax and AUC0-∞ higher than IV administration (2.3- and 2.88-fold, 
respectively). This study confirmed the direct transport of resveratrol into the brain with 458.2% drug targeting efficiency 
(DTE%) and 78.18% brain drug direct transport (DTP%) [116]. Whether resveratrol has been confirmed for Alzheimer’s 
disease treatment or not, this study ensured a way for delivery and maximizing brain concentration where other routes failed to 
produce tangible evidence for brain targeting. Examples of recent intranasal nanosuspensions are listed in Table 3. 
Table 3. Nanosuspension-based intranasal formulations. 
API Target Composition Particle size Model/Compared 
compartment 
Observations Refs 
Carvedilol  Systemic  Poloxamer 
407, oleic 
acid, and 
gellan gum 
190 nm  Rabbits/ Oral 
suspension and IV 
solution  
2.4-fold higher 
Cmax and 2.6-fold 
higher AUC0–∞ 
with 69.4 % 
absolute 
bioavailability 
were achieved 
[117
] 
Meloxicam Systemic  Polyvinyl 
alcohol, and 
sodium 
hyaluronate  
135 nm Rats/ Micronized 
(1.9 μm particle 
size) and raw 
meloxicam spray 
3-fold higher 
plasma level was 
observed after 5 
min 
[118
] 
Ezogabine  Brain  Tween® 80, 
and 
Poloxamer 
188  
155-454 nm  Ex vivo/ Not 
recorded 
Maximum 97.9% 
of ezogabine 
released within 6 h 
and no cilio-
toxicity was 
observed 
[119
] 
 
Studies on the nasal application of nanosuspensions reported an average size with the range 140-500 nm. Moreover, the use of a 
mucoadhesive agent such as chitosan and the preparation of in situ gel are common procedures in the practice. Besides the 
systemic target, brain delivery has been significantly considered in the recent studies. 
4.2 Intranasal Lipid and Surfactant-Based Nanoparticulate Drug Delivery Systems 
Lipid nanoparticles show a promising approach for intranasal delivery. The advantages of active agent protection from 
enzymatic degradation, capability for hydrophilic as well as lipophilic molecule delivery, low toxicity, good permeability, and 
the possibility of modifications and adaptations have justified their wide application for the intranasal route. These systems 
include liposomes, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), niosomes, nanoemulsions (NE) and 
nanocapsules (NC) [120,121]. 
4.2.1 Liposomes  
Liposomes are spherical vesicles containing one or more lipid bilayers that encapsulate aqueous drug compartments with a 
diameter in the range of 400 nm-2.5 µm. The properties of the lipid structure have a significant effect on the liposome surface 
charge, membrane flexibility, and the surface hydration and particle size [122]. These factors affect the kinetics of liposomes, 
bio-distribution, and faith after administration [123]. Liposome properties on uptake enhancement, and toxicity minimization 
were earlier explored by Kimelberg et al [124]. 
The intranasal delivery of liposomes showed an efficient delivery of calcitonin based on what has been discussed by Law et al. 
[125]. The effects of the type and charge of liposomes on calcitonin loading efficiency were verified; anionic liposomes showed 
higher loading efficiency than neutral and cationic ones. Loading efficiency increased with calcitonin concentration. The 
evaluation of the effects of calcitonin liposomes on bioavailability was accomplished with in vivo studies. The intranasal 
absorption of calcitonin was enhanced compared to the calcitonin solution; particularly, with positively charged liposomes, 
these findings confirmed the effects of different factors on the intranasal application of liposomes. The positively charged 
liposomes showed higher calcitonin bioavailability than the negative liposomes due to their higher contact time with the 
negatively charged mucosal membrane, thus lowering mucociliary clearance [126]. Alternatively, Chen et al [127] evaluated 
the usage of ultra-flexible liposomes on salmon’s calcitonin intranasal absorption. There were no differences in the absorption 
between negative and positive liposomes, which was attributed to the rapid absorption of calcitonin from the liposomes. 
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Insulin-loaded liposomes showed low permeability through the nasal mucosa in the rabbit model. On the other hand, the 
permeability of insulin entrapped in the liposomes was increased after using sodium glycocholate as a penetration enhancer 
[128,129]. The importance of liposomes for insulin delivery has been reported in the work of Jain et al [130]. The authors 
reported that chitosan-coated multiple vesicular liposomes were able to control the plasma glucose level in diabetic rats for two 
days. This sustained pattern can overcome the inconvenience of rapid increase followed by a rapid decline of insulin serum 
concentration after the intranasal administration. In spite of the feasibility of the intranasal use for sustained delivery, chronic 
application is controversial and to date, it is not practical [131]. 
The brain delivery of the intranasal liposomes has been investigated by using ovalbumin as a model peptide. Both 
transportation into brain and brain residence time have been enhanced compared to the solution preparation. In this study, 
cationic liposomes with an average size of 299 nm showed high loading efficiency and more than 90% drug delivery to the 
brain. Intranasal delivery depended on the concentration and volume of the administration in a pattern that smaller volumes of 
the liposomal preparation enhanced retention and reduced swallowing, thus promoting brain delivery [132]. 
Liposome contribution in intranasal mucosal vaccinations is related to the retention enhancement of the liposome inside the 
nasal cavity, therefore, the high chances of antigen delivery by M cells located on the NALT. Moreover, liposomes are able to 
induce immunoadjuvant activity [133,134]. Wong et al [135] showed that intranasal liposomes of hemagglutinin - the influenza 
antigen - induced serum the IgG levels higher than the naked antigen. Furthermore, modified liposomes showed enhanced 
delivery; for instance, chitosan-modified liposomes facilitated the interactions with the negatively charged mucosal surfaces 
and produced a great potential for DNA delivery. In another aspect, galactose-modified liposomes of ovalbumin showed a 
higher macrophage uptake and induced both mucosal IgA and serum IgG in a mouse model [96,136]. These findings 
highlighted the importance of modified liposomes in antigen delivery [137,138]. 
4.2.2 Solid lipid nanoparticles (SLNs) 
Solid lipid nanoparticles are another example of lipid-based systems that have shown promising prospects for intranasal 
delivery. These systems are characterized by a 50-1000 nm range of particle size, they are composed of physiological lipids, 
and stabilized by nontoxic surfactants like Poloxamer and lecithin. The attractiveness of these systems is based on their safety 
compared to polymeric nanoparticles, and the low production cost compared to liposomes. They can be formulated by simple 
methods like high pressure homogenization and microemulsions [139]. Intranasal alprazolam-loaded SLN using Tween® 80 
and Pluronic® F68 had an average diameter of 99.5 nm and entrapment efficiency of 40.3%. These SLNs showed higher brain 
bioavailability of alprazolam than with IV administration, with 55% DTP and 224% DTE. The intranasal SLN of budesonide 
showed higher permeation values than the free drug and the already marketed formulation of budesonide by 3.4- and 1.8-fold, 
respectively. [140,141]. In a study to prepare agomelatine SLNs with the emulsification solvent evaporation technique, the 
optimized SLN showed a particle size of 167 nm, polydispersity index of 0.12 and entrapment efficiency of 91.3%. This 
optimized formulation exhibited a substantial increase in each of the plasma peak concentration, the AUC (0–360 min) and the 
absolute bioavailability compared to those of the oral marketed dosage form with the values of 759.00 ng/mL, 7,805.69 
ng⋅min/mL and 44.44%, respectively. The SLN of agomelatine also revealed DTE of 190.02 and DTP of 47.37, thus higher 
brain targeting by the intranasal delivery than by the IV route [142]. 
4.2.3 Nanostructured Lipid Carriers (NLCs) 
These systems, composed of both solid and liquid lipids as a core, offer the advantages of higher loading capacity than SLNs 
without undergoing polymorphic transition and drug explosion during storage [139]. Intranasal NLCs have been utilized for the 
brain targeting of temozolomide -an antitumor agent- in a recent study. In this study, NLC protected the drug from the p-gp 
system by the effects of Poloxamer 188, which also increased drug mucosal penetration. As a result, the brain concentration of 
temozolomide was higher than what has been achieved after IV administration with a sustained effect. Thus, it can provide a 
direct delivery for the treatment of brain tumors [143]. In another scope, the exceptional particle size, mucoadhesivity, and 
rapid release properties of tetrahydrocannabinol cationic NLC formulation raised the opportunity for the novel nasal spray to 
control cancer breakthrough pain [144]. 
4.2.4 Niosomes 
Niosomes are structurally similar to liposomes in the concept of bilayer systems that entrap drugs with a chief difference in 
composition. Unlike liposomes, niosomes are composed of non-ionic surfactants that are responsible for a vesicle-like structure, 
thus providing more stability over liposomes by removing the inconvenience of oxidation and the purity variation of 
phospholipids [145]. The assembly of non-ionic surfactants into closed bilayers can be spontaneous or with the help of external 
stimuli, such as heat or shearing forces. Besides the activity of niosomes as hydrophilic and lipophilic drug carriers, they act as 
solubility enhancers, hence increasing the bioavailability of poorly water-soluble drugs. The main limitations of niosomes 
include aggregation, fusion, and leakages during storage. These adverse properties of niosomes can be minimized by additives 
such as cholesterol, fatty alcohols, charge inducers (dicetyl phosphate and stearylamine) or steric groups on the surface of 
niosomes [146]. 
Niosomes for intranasal application have been proposed to represent a promising approach for enhanced and controlled 
delivery. Intranasal folic acid niosomes intended for brain targeting have shown controlled ex vivo perfusion [147]. Regarding 
the systemic effects of intranasal niosomes, diltiazem-loaded niosomes have shown high half-life (T1/2 ) and enhanced AUC 0-∞ 
with a reduced elimination rate; such prolonged action for diltiazem is of great value compared to its low oral bioavailability 
due to extensive first-pass metabolism [148]. The study of using intranasal niosomes for vaccination with glycoprotein B of 
herpes simplex virus type 1 has shown in vitro controlled release and in vivo elicited plasma glycoprotein antibodies (IgG) and 
systemic T helper cells [149]. These outcomes demonstrated the efficacy of niosomes to produce immunity against genital 
herpes in the female murine animal model and generalized the activity of niosomes for vaccination. 
4.2.5 Nanoemulsions (NEs) 
Nanoemulsions are part of a nanoparticulate system with a typical particle size of less than 200 nm. These systems contain oil, 
water, and surfactants, and are characterized by simple preparation methods, biocompatible constituents, and robust stability 
against sedimentation, creaming, dilution, and temperature effects. NEs could enhance drug solubility and mucosal permeation 
[150]. Regarding their nature and the possibility for the addition of excipients, such as mucoadhesive and gel-forming 
polymers, NEs can provide a novel intranasal delivery system that meets the criteria of drug protection, mucosal adhesion, and 
permeation enhancement [151]. Intranasal NEs have been studied for their activity on systemic, brain targeting, and vaccine 
delivery, but not for local delivery due to the effect of absorption that would transfer the drug from the local site to the systemic 
circulation or even the brain. For example, intranasal nitrendipine NEs have shown a rapid onset of action with a relative 
bioavailability of 60% compared to the marketed oral tablets [152]. The preparation of NE in situ gel was proposed to be 
effective in enhancing systemic absorption based on the results of zaleplon; rapid absorption with Tmax of 20 min and 8-fold 
higher bioavailability compared to the marketed tablets. These results could be attributed to the effects of gel-forming polymers 
on residence time enhancement and permeation improvement [153]. 
The utilization of NEs in vaccine delivery has been receiving focused attention in many studies. NEs may exhibit a strong and 
broad antimicrobial, antiviral, and antifungal activity and provide good adjuvant activity. Many studies have demonstrated the 
efficacy of NE-based mucosal vaccinations against many infections, particularly, influenza and respiratory syncytial viruses 
[154–158]. For example, a W805EC adjuvant NE with 400 nm globules successfully enhanced the immune humoral response 
in murine animal model [157]. A recombinant HIV gp120 antigen NE showed the mucosal adjuvant activity of the NE for 
multivalent HIV vaccines [156]. Moreover, Sun et al [159] reported the adjuvant activity of the NE against methicillin-resistant 
Staphylococcus aureus (MRSA). This study reported a novel NE containing MRSA recombinant protein with an average 
diameter particle size of approximately 31 nm. The mucosal vaccine showed improved immune responses without using 
additional adjuvant additives. 
4.2.6 Nanocapsules (NCs) 
Nanocapsules are composed of an oily core surrounded by a polymeric coat (shell) with a general range of particle sizes of 
100–500 nm. NCs have been one of the systems in the focus of research due to their promising potential as an effective drug 
delivery platform for the transmucosal administration of peptides, vaccines, and hydrophilic and lipophilic drugs. The 
development of NCs has emerged from the ability to control particle size, surface properties, and composition. Therefore, 
control over stability and interaction with the mucosal membranes are attainable [160]. 
Importance has been given to the systemic delivery of intranasal peptides using NCs by the work of Prego et al [161]. In this 
study, salmon calcitonin was used as the model peptide and was incorporated into the chitosan-coated oil NCs. The results 
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showed that NCs with sizes in the range of 200-570 nm led to hypocalcemic effects that were considerably enhanced and 
prolonged compared to the corresponding salmon calcitonin nanoemulsion or to the aqueous solutions with chitosan. 
Sallam et al [162] developed a locally acting nasal delivery system of triamcinolone acetonide using different nanosystems. The 
NCs composed of a Capryol® oily core and Eudragit RS100 provided the highest mucosal retention compared to the NEs and 
NLCs with the least permeation, thus the drug was retained on the nasal mucosa. Moreover, NCs also showed lower mucosal 
irritation and superior stability compared with NEs. The identification of the intranasal NCs as a brain delivery approach has 
been discussed in different studies. For example, Clementino et al [163] reported the NC systems for brain delivery of 
simvastatin. The drug was loaded in lecithin/chitosan and the system was characterized by a particle size of 200 nm, 
encapsulation efficiency of 98%, and zeta potential of +48. These NCs showed that around 20% of the dose was accumulated in 
the brain whilst the drug nanosuspension distributed the drug into other body organs and a very limited amount in the brain. 
Vicente et al [164] reported a remarkable example for using NCs in the nasal system for the co-delivery of viral proteins and 
imiquimod for vaccination purposes. In this study, imiquimod, a lipophilic immunostimulant, was added in the oily core whilst 
the recombinant hepatitis B surface antigen (HB) was associated with the chitosan shell. The system showed a particle size of 
around 200 nm, zeta potential of +45 mV, and antigen association efficiency of 70%. As a result, the NCs containing 
imiquimod elicited a protective immune response and showed increased IgG levels and specific immunological memory. 
Moreover, a balanced cellular/ humoral response was achieved indicating the capacity of the NCs to modulate the systemic 
immune response upon nasal vaccination. 
NCs are widely reported as NEs with mucoadhesive polymers. The advantages of NCs over conventional NEs were confirmed 
in many studies. For example, intranasal risperidone NE showed enhanced brain and plasma concentrations compared to the 
drug solution, and it was comparable to the IV injected formulations. However, the NE with chitosan (NCs) formulations 
showed a significantly higher Cmax and AUC in addition to higher brain targeting (approximately 2-fold higher DPT%) [165] 
The same effects have been achieved with olanzapine. A mucoadhesive NE of olanzapine showed a higher brain AUC0-∞ 
compared to a NE without mucoadhesive polymer and also showed a 2-fold higher brain bioavailability than the IV injected 
drug [166]. Recently, Colombo et al [167] investigated the brain delivery of an intranasal NE containing kaempferol for glioma 
cell targeting. This study showed the enhanced delivery effects of the chitosan-based mucoadhesive NE compared to the NE 
without chitosan. A mucoadhesive NE of zolmitriptan is another example that showed the enhanced brain permeation of 
zolmitriptan from a chitosan-based mucoadhesive NE. A 2.8-fold higher brain AUC (0-8) compared to the IV and brain targeting 
parameters of 164.77 and 9.61 for DTE% and DTP%, respectively, were attained [168]. Other studies investigated hyaluronic 
acid for the development of mucoadhesive nasal NEs for brain delivery. For example, resveratrol and curcumin were 
formulated together into a lipidic NE using hyaluronic acid as the mucoadhesive agent. The NEs showed brain target ability in 
a manner of about 7- and 9-fold increase in brain AUC0–7 h for resveratrol and curcumin, respectively [169]. 
Literature on lipid- and surfactant-based nanoparticles demonstrated the significance of these systems for nasal delivery. These 
systems were characterized as having a particle size in the range of 75-300 nm. However, the particle size was dramatically 
increased when proteins and peptides were loaded and when multilamellar vesicles were prepared as shown with the next 
tabulated examples. Several examples have shown the usage of gelling, mucoadhesive, functionalized polymers and other 
additives to ensure the nanoparticles’ properties and efficiency. Therefore, the selection of the constituents and their 
concentrations is very valuable to get the attributed quality, safety, and efficacy [158]. Table 4 shows the recent researches of 
intranasal lipid nanoparticulate systems.  
Table 4. Recent examples of intranasal lipid nanoparticulate systems. 
API Target Systems Composition Characterization Model/compa
red 
parameter 
Results Ref. 
Acyclovir  Systemic  Liposomes DPPC, CHOL, 
PVP, and PEG 
600 
627.4 nm and 43.2% 
entrapment efficiency 
Rabbits/ IV 
 
The bioavailability of 
acyclovir has been 
increased to 60% 
[170] 
Fexofenadine  Systemic  Liposomes  DPPC, DPPG, 
CHOL, and 
chitosan 
359 nm and 66.1% 
entrapment efficiency  
Rat/ Oral  Chitosan-coated 
liposomes showed 5-fold 
higher bioavailability 
with slower release, 
lower Cmax, and 1.3-fold 
higher T1/2 
[171] 
Risperidone  Brain  Liposomes Stearylamine and 
MPEG-DSPE 
90-100 nm with 50-
60% entrapment 
efficiency  
Rats/ Pure 
drug IV bolus 
PEGylated liposomes 
had 2.3-fold higher brain 
Cmax, 1.7-fold higher 
AUC0-∞, 4 times shorter 
Tmax, and 2.6 higher T1/2 
[113] 
Rivastigmine  
 
Brain Liposomes  Lecithin, DDAB, 
and PEG-DSPE 
478 nm and 48 % 
entrapment efficiency  
Rabbits/ IN 
drug solution  
The stealth liposomes 
showed 1.6-fold higher 
brain Cmax, 5-fold longer 
Tmax, 5.5-fold higher 
AUC0–∞, and 4.2-fold 
higher plasma AUC0–∞ 
compared to the IN drug 
solution 
[172] 
Donepezil Brain  Liposomes CHOL, PEG, and 
DSPC 
102 nm and 84.9% 
entrapment efficiency  
Rats/ Oral, IN 
free drug  
The liposomes showed 
higher Cmax for IN 
delivery with reduced 
Tmax. Moreover, 
enhanced brain and 
plasma bioavailability 
were achieved as the 
liposomes had shown 2-
fold higher plasma 
AUC0–∞, 2-fold higher 
Cmax, and 1.5-fold higher 
brain AUC0–∞ compared 
to the IN free drug 
[173] 
Astaxanthin  Brain SLN Stearic acid, 
Poloxamer 188, 
and lecithin 
213.2 nm and 77.4% 
entrapment efficiency  
Rats/ IV SLN  SLN showed 2-fold 
higher brain level after 1 
h with lower blood level 
compared to the IV 
delivery 
[174] 
Quetiapine  Brain  SLN glycerol 
monostearate and 
Span-80 
117.8 nm with 97.5% 
encapsulation 
efficiency  
Rats/ Tail IV, 
oral drug  
The in situ gel of 
quetiapine showed 
similar blood and brain 
concentration as the IV 
delivery of the drug, but 
higher than the oral 
delivery 
[175] 
H102 Peptide 
 
Brain Liposomes EPC, PEG-DSPE, 
and CHOL 
112.2 nm and 
71.35% encapsulation 
efficiency  
Rats/ IN drug 
solution  
Liposomes effectively 
delivered the peptide 
into the brain. The 
liposomes showed higher 
H102 concentrations at 
different brain regions 
with the maximum 
concentration being 
identified in the 
hippocampus 
[176] 
Galanthamin
e 
hydrobromid
e 
Brain Liposomes PG, SPC, and 
CHOL 
112 nm and 83.6% 
encapsulation 
efficiency  
Rats/ Oral drug 
solution  
The flexible liposomes 
showed 3.52-fold higher 
Cmax, 3.36-fold higher 
AUC0-∞, and Tmax 
shortened to half 
compared to the orally 
[177] 
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administered drug 
GDNF Brain Liposomes DOPC, CHOL, 
and stearylamine  
194 nm and 95% 
loading efficiency   
Rat/GDNF 
solution  in 
PBS 
The liposomes showed 
10-fold more GDNF 
delivery than the PBS 
with the same 
neuroprotective efficacy 
[178,
179] 
Haloperidol Brain SLN GMS and Tween® 
80 
140 nm, 71% 
entrapment efficiency 
and 23% drug 
loading 
Rats/ IN drug 
solution  
SLN showed 3.6-fold 
higher brain Cmax and 
3.5-fold higher AUC0-∞ 
[180] 
Protein 
antigen 
HBsAg  
Vaccinatio
n 
 
Liposomes EPC, CHOL, and 
PAA 
773 nm with 53.3% 
encapsulation 
efficiency 
Mice/ IM 
 
Gel core liposomes 
induced serum and 
mucosal immunity with 
comparative serum IgG 
to IM. Moreover, IN 
induced significant sIgA 
that IM failed to produce 
with significant 14th day 
boosting  
[181] 
Lipopeptide-
based against 
Group A 
streptococcus 
Vaccinatio
n 
 
Liposomes DDAB, DPPC, 
and CHOL 
160 nm and 98% 
encapsulation 
efficiency  
Mice/ IN 
unmodified 
peptide  
The prepared cationic 
liposome containing the 
lipopeptide induced both 
mucosal and systemic 
immunity and a high 
level of titer after 5 
months’ post-
immunization. 
Furthermore, high IgG 
and IgA titers were 
measured 
[182] 
OVA Vaccinatio
n 
Liposomes DOTAP and DC-
chol, CHOL 
57-846 nm Mice/ Nasal 
naked OVA 
Liposomes were 
prepared by using 
DOTAP and DC-chol or 
by DOTAP and CHOL. 
The cationic liposomes 
induced a Th2 immune 
response with high levels 
of IL–4 expressions with 
adjuvant activity. 
DOTAP/DC-chol 
liposomes induced 
potent antigen-specific 
IgG serum responses that 
were superior to 
DOTAP/chol liposomes. 
Moreover, the liposomal 
activity was independent 
of particle size 
 
[183] 
DNA-hsp65 Vaccinatio
n 
 
Liposome EPC, DOTAP, 
and DOPE 
244.5, 985.9 nma 
616.7, 2749.6 nmb 
Mice/IM 
naked DNA  
Liposomes contained 
DNA or were complexed 
with the DNA on the 
surface and produced a 
significant reduction in 
the number of bacilli in 
[184] 
the lungs with 16-fold 
reduction in the required 
DNA amount. These 
liposomes were cationic 
with no toxic effects 
BSA as 
model 
antigen 
Vaccinatio
n 
Liposomes SPC, DMPG 
CHOL, SA, and 
alginate, chitosan, 
and TMC 
303-996.4 nm with 
60-69% 
encapsulation 
efficiency  
Ex vivo  
 
The particle size was 
increased dramatically 
after coating with 
polymer. TMC amongst 
others showed the best 
mucoadhesive 
capabilities. However, 
the TMC-coated 
liposomes showed a low 
mucosal penetration due 
to due to their high 
particle size 
[185] 
Streptomycin 
sulfate 
Brain and 
systemic  
SLN Compritol® 888 
ATO, Tween® 80, 
and soy lecithin 
140 nm and 54.8% 
entrapment efficiency  
Mice/ IN Free 
drug  
Streptomycin-SLN 
showed 3.15- and 11-
fold higher brain and 
plasma concentrations 
and less accumulation in 
the kidneys, liver, and 
spleen with 3.3, 12, and 
4 times lower 
concentrations, 
respectively, being 
observed 
[186] 
Rizatriptan 
benzoate 
Brain SLN Lecithin, 
Pluronic® 127, 
and GMS 
145-298 nm and 59-
80% encapsulation 
efficiency  
Rats/ IV free 
drug, oral 
marketed drug  
The optimized rizatriptan 
SLN showed an 
enhanced T1/2 and higher 
CSF concentrations by 
1.3- and 5.46-fold 
compared to the IV and 
oral, respectively. The 
SLNs also showed a 
shortened Tmax 
[187] 
Venlafaxine Brain NLC Compritol®  888 
ATO, and 
Capmul® MCM  
75 nm and 81.4 % 
entrapment efficiency  
Ex vivo NLC of the venlafaxine 
showed a 1.5-fold higher 
flux and 1.5-fold higher 
diffusion coefficient 
compared to the free 
drug solution across the 
goat’s nasal mucosa  
[188] 
Asenapine Brain NLC GM and oleic 
acid 
167.3 nm and 83.5% 
encapsulation 
efficiency  
Rats/ IN free 
drug  
NLC showed a higher 
brain concentration of 
Asenapine compared to 
the IV delivery for the 
drug with 1.8- and 2.7-
fold Cmax and AUC0-24, 
respectively, being 
achieved. Moreover, 
Asenapine showed 
276.7% brain 
bioavailability. There 
were marked increases 
of the antipsychotic 
effects 
[189] 
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Olanzapine Brain  NC poly(ε-
caprolactone) and 
Poly(MMA-b-
DMAEMA) 
254.9 nm and 99% 
encapsulation 
efficiency 
Rats/ 
Olanzapine 
solution  
The olanzapine-loaded 
amphiphilic methacrylic 
copolymer-
functionalized PCL NC 
enhanced the amount of 
the drug in the brain 
(1.5-fold higher 
compared to the drug 
solution) 
[190] 
Loratadine  Local  Niosomes-
in situ gels  
CHOL, various 
Span surfactants, 
Carbopol® 934, 
and Poloxamer 
407 
266 nm with 89-97% 
drug content  
Ex vivo  Niosomes were 
formulated into an in situ 
gel and they showed a 
high residence time and 
sustained drug release. 
[191] 
Melatonin Systemic  Niosomes  CHOL, Span 60, 
and SDC 
 
100 nm and 84-94% 
encapsulation 
efficiency  
Rats/ IV 
melatonin 
solution  
SDC increased 
encapsulation efficiency. 
The niosomes of 
melatonin with SDC 
showed 98.7% 
bioavailability compared 
to the IV delivery 
[192] 
Quetiapine Brain  NE Transcutol® P, 
Capmul® MCM, 
PG, and Tween® 
80 
144 nm and 91% 
drug content  
Rats/ IV pure 
drug solution  
QTP-loaded NE showed 
a 267.89 DTE% and  
63.63 DTP%, thus the 
superiority of brain 
targeting. 
 
[193] 
Tramadol Brain NE IPM, Soya 
lecithin, and 
Poloxamer 188 
136.3 nm and 99.16% 
entrapment efficiency 
Mice/ IV and 
nasal drug 
solution  
Tramadol-loaded NE 
enhanced 
antinociception at most 
measurement time points 
compared to the nasal 
and IV solution. 
Moreover, NE showed 
116.89 DTE% and 98.06 
DTP% parameters. 
[194] 
Quercetin Brain NE Oleic acid, PEG 
400, Tween® 80, 
Labrasol®, and 
Transcutol® HP 
91.6 nm and 99.8% 
drug content  
Rats/ IV NE  Quercetin-NE improved 
neurobehavioural 
activity and reduced 
infarction volume effects 
in middle cerebral artery 
occlusion. Moreover, 
4.8-fold higher brain 
Cmax and 5.3-fold higher 
brain AUC0-t, 9333.3% 
DTE, and 2181.8% DPT 
were achieved 
[195] 
Thymoquino
ne 
Brain  NE Oleic acid, 
Carbitol™, 
Tween® 20, 
Labrasol®, and 
Cremophore EL  
94.8 nm and 99.9 
drug content 
Rats/ IV 
solution 
The mucoadhesive NE 
improved the 
neurobehavioural 
activity in middle 
cerebral artery occlusion 
and showed 628.6 DTE 
and 90% DTP brain 
parameters for 
thymoquinone 
[196] 
Saquinavir 
mesylate 
 
Brain  NE Capmul® MCM, 
Tween® 80, and 
PEG 400 
176 nm with 96% 
drug content   
Rats/ IV NE  NE showed 2919.3 
DTE% and 96.6 DTP%, 
suggesting brain 
targeting 
[197] 
Sertraline  Brain  NE Capmul® MCM, 
Tween® 80, and 
PEG 
78 nm whilst the drug 
content was not 
recorded 
Ex vivo  Ex vivo showed a 62% 
nasal absorption for 
sertraline through a 
goat’s nasal mucosa 
within 4 h  
[198] 
TNFα siRNA Brain  NE  Flaxseed oil, 
DOTAP, Lipoid 
E80, and Tween® 
80 
69-166 nm and 70% 
encapsulation 
efficiency 
Rats/ Naked 
siRNA  
5-fold higher brain 
uptake and the NE of 
TNFα siRNA markedly 
reduced the unregulated 
levels of TNFα in an 
LPS-induced model of 
neuroinflammation 
[199] 
OMP 
antigen- 
Burkholderia 
cenocepacia 
bacteria 
Vaccinatio
n 
NE  The compositions 
were not 
recorded. 
However, NE was 
supplied by 
BlueWillow 
Biologics 
(Michigan, USA) 
Not recorded Mice/ OMP-
PBS 
OMP-NE-loaded antigen 
elicited high OMP-
specific IgG antibodies 
with response to booster 
immunisation (13-30-
fold higher than OM-
PBS). Also a high rate of 
pulmonary clearance of 
bacteria was observed 
[200] 
OVA antigen  Vaccinatio
n 
NE  Oleic acid, 
mannide 
monooleate, and 
Tween® 80 
153 nm whilst the 
content of the OVA 
antigen was not 
recorded 
Mice/ OVA 
antigen  
Oleic acid NE showed 
high IgA and serum IgG 
for the 45th day and 
induced mucosal 
immunity with single 
booster immunization 
[201] 
W805EC Vaccinatio
n 
NE NE was supplied 
by BlueWillow 
Biologics 
(Michigan, USA) 
424-774 nm whilst 
the content of the 
W805EC was not 
recorded 
Mice/Vaccine 
in  phosphate 
buffer  
The NEs showed that 
high hemagglutination 
titers of serum and high 
influenza-specific IgG 
and IgA titers, also high 
IgA levels in the 
bronchoalveolar lavage 
were achieved in 
comparison to the 
vaccine in the phosphate 
buffer. However, NEs 
with 1:6 ratio of 
cationic-to-non-ionic 
surfactants and 450 nm 
globule size elicited 
significantly higher 
influenza-specific IgG 
serum antibody titers 
than any other 
formulation 
[202] 
Recombinant 
hepatitis B 
surface 
antigen 
(HBsAg) 
Vaccinatio
n 
NE NE was supplied 
by BlueWillow 
Biologics 
(Michigan, USA) 
349 nm whilst the 
content of the HBsAg 
was not recorded 
Mice/Antigen 
in PBS 
Robust and sustained 
systemic IgG, mucosal 
IgA, and strong antigen-
specific cellular immune 
responses were 
observed. Moreover, this 
vaccine induced a Th1 
associated cellular 
immunity 
[203] 
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Abbreviations: DPPC, L-α-dipalmitoylphosphocholine; CHOL, cholesterol; PVP, polyvinylpyrrolidone; PEG, polyethylene glycol; DPPG, 
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol; DSPE-PEG, distearylphosphatidylethanolamine-mPEG; DDAB, Didecyldimethyl ammonium 
bromide; DSPC, 1,2-distearyl-sn-glycero-3-phosphocholine; EPC, egg phosphotidylcholine; PG, propylene glycol; SPC, Soya phosphatidyl- 
choline; DOPC, dioleoylphosphatidylcholine; PBS, phosphate buffer saline; GMS, Glyceryl monostearate; PAA, poly acrylic acid; DOTAP, 
1,2-dio- leoyl-3-trimethylammonium-propane; DC-chol,  3β-[N-(N',N'-dimethylaminoethane)-car- bamoyl]; MMA, methyl methacrylate; 
DMAEMA, 2-(dimethylamino)ethyl methacrylate; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DOPE, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine; SPC, soy phosphatidylcholine; DMPG, phospholipid dimyristoyl phosphatidylglycerol; TMC, trimethyl chitosan; SDC, 
sodium deoxycholate; IPM, isopropyl myristate; LPS, lipopolysaccharide; GDNF, Glial cell-line derived neurotrophic factor; OVA, 
Ovalbumin; PBS, phosphate-buffered saline; IL-4, Interleukin 4; Th2, T helper cells 2; min, minutes; h, hour; IN, intranasal.                                                       
Notes: a entrapping DNA-hsp65, b complexing DNA-hsp65 
4.3 Intranasal Polymeric-Based Systems 
Polymeric-based nanoparticles have become one of the most applied methods for drug delivery due to their characteristics of 
high drug loading, stability, and a variability of loading substances, including peptides, vaccines, and genes in addition to 
surface modification possibilities and the ability of controlled release. Polymeric-based nanoparticles include degradable and 
nondegradable polymers as well [204]. 
4.3.1 Biodegradable nanoparticles (BNPs) 
Many polymers have been introduced for the intranasal delivery of nanoparticles like polysaccharides (chitosan); polyester 
derivatives, such as polylactic acid (PLA) and poly (lactide-co-glycolide) PLGA; proteins (Lectins); poly(ethylenimines); and 
poly(alkylcyanoacrylates). The selection of the proper type and modifications depend on many factors, such as encapsulation 
efficiency, particle size, and stability. Amongst these polymers, both chitosan and PGLA have been found to be the most 
promising. Both polymers are safe according to the FDA and are characterized by biocompatibility, biodegradability, and the 
ability for encapsulation of a wide range of hydrophilic, lipophilic, small, and large molecules with protection capabilities, in 
addition to the possibility of the modification to improve the BNPs properties and their interactions with the biological 
materials [205,206]. 
The positive charge of the chitosan derivative is of high value for the intranasal delivery through increasing the contact time 
with the mucosal tissue. Its contribution in intranasal delivery has been proved via many types of research that have covered 
many aspects. Levodopa-chitosan-loaded nanoparticles were formulated as a thermoreversible gel for brain targeting. 74% of 
the drug was retained in the brain. However, gel formulation may hinder delivery due to its high viscosity and its effects on the 
ciliary beating [207,208].  
Intranasal delivery of PLGA-tarenflurbil nanoparticles can prevent the elimination of this drug as a possible drug candidate for 
Alzheimer’s treatment when its poor BBB penetration was responsible for its failure in phase III clinical trials [209]. 
Muntimadugu et al [210] showed that intranasal delivery of PLGA nanoparticles successfully targeted the brain with a 4-fold 
higher tarenflurbil brain concentration than with oral delivery and 1.5-fold higher than in the case of IV delivery. This study 
also showed the superiority of polymeric nanoparticles over SLNs in terms of loading efficiency and brain delivery. However, 
SLNs are still an option for direct drug to brain delivery. 
The variability of nanoparticles to include mRNA possesses a great value for vaccination against tumors. The nasal delivery of 
cancer vaccination was tested by Phua et al [211] on mice. The results showed delayed tumor progression in both prophylactic 
and therapeutic models compared to the naked delivery. This effect can be attributed to the protection against enzymes and an 
efficient delivery as expressed by 24-hour-long luciferase expression. In the same field, Matsuo et al [212] reported the effect 
of ovalbumin- poly(γ-glutamic acid) nanoparticles. The results showed the activity of nanoparticles against E.G7-OVA tumor 
cells; tumor growth was suppressed and survival time was enhanced in mice models. Moreover, the inhibitory effect was 
extended to lung metastasis in a similar way as with subcutaneous (SC) injections. In another research, siRNA-loaded chitosan 
nanoparticles with 141 nm size and 81% encapsulation capacity targeted Galectin 1 (Gal1), the potent immunosuppressive 
protein regulator in glioblastoma that induces the apoptosis of T cells and is the main contributor to glioblastoma resistance 
against temozolomide. The results showed a significant reduction of Gal 1 in both murine and human tumor cells with the 
subsequent reduction in Gal 1 mobility. The in vivo studies showed the applicability of the siRNA delivery to the brain via 
intranasal nanoparticles with a significant reduction of Gal 1. Chitosan offered the rapid attachment of the cells and protected 
the siRNA from RNAse degradation [213]. 
4.3.2 Dendrimers  
Dendrimers are highly branched three-dimensional nanomaterials which have been introduced as drug carriers either via 
covalent conjugation with the drug molecule or drug (guest) hosting. These two options are attributed to their structure; they 
contain a large number of surface functional groups and a hydrophobic cavity that can enhance drug penetration through the 
mucosal membranes [214]. The advantages of dendrimers include internal cavity, particle size, and morphology control, in 
addition to their solubility enhancement, which allows the use of dendrimers for many drug formulations. Moreover, modified 
dendrimers have been targeted as nanomedicine against tumors, viral, and bacterial infection particles. Some of these products 
have been marketed successfully [215–218]. 
The first and most reported dendrimer type used in intranasal delivery was polyamidoamine (PAMAM). Kim et al [219] 
investigated using PAMAM as a siRNA gene carrier for the high mobility group box 1 (HMGB). The results of the reduced 
brain infraction volume were a proof for the activity of siRNA dendrimers as an efficient knock-down of HMGB [212]. In 
another study, the PAMAM formulation of haloperidol intended for brain targeting showed 100-fold higher solubility with 
significant brain and plasma concentrations, resulting in a 6.7-fold smaller dose being required to produce a response similar to 
the intraperitoneal (IP) injection [220]. Additionally, PAMAM showed substantial effects on the nasal absorption of poorly 
absorbed molecules, namely calcitonin, insulin, and fluorescein isothiocyanate-labelled dextran, as it was pointed out via in 
vivo studies using a rat model [221]. Both plasma concentration and AUC were increased. This study revealed a positive 
relationship between PAMAM molecular weight and its delivery enhancing effect. Beyond the benefits, toxicity is the major 
challenge for dendrimers. Toxicological effects are related to the generation number, concentration, contacting time, and is 
connected to their absorption enhancement capacity [222]. 
The application of dendrimers in intranasal delivery should be evaluated in regard to the host-guest relationship with paying 
attention to the guest properties, such as hydrophobicity and size for efficient binding or encapsulating. Furthermore, possible 
toxicity must be addressed cautiously [223,224]. 
According to the scientific literature, polymeric-based systems can meet the need for efficient intranasal delivery. Table 5 
displays the most recent studies of these systems. 
Table 5. Recent examples of intranasal polymeric-based nanoparticles. 
 
API Target Syste
m 
Composition Characterization Model/compa
red 
parameter 
Observations Refs . 
Olanzapin
e 
Systemi
c 
BNP Chitosan and TPP 208-322 nm and 
87% encapsulation 
efficiency  
Rabbits/ IV 
free drug  
Olanzapine-loaded 
chitosan showed 51% 
absolute bioavailability 
and Tmax similar to the IV  
[225] 
Donepezil  Brain  BNP Chitosan and TPP 150-200 nm Rats/ Free 
drug 
suspension  
Brain Cmax and AUC0–∞ 
were enhanced by 3.7- 
and 1.57-fold, 
respectively. 
[226] 
Acetazola
mide  
Brain  BNP Chitosan and TPP 153-277 nm Ex vivo/ Free 
drug  
Maximum 64% of 
acetazolamide was 
released within 4 h and 
no toxicity was observed 
[227] 
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Olanzapin
e 
Brain  BNP PLGA and 
Poloxamer 407 
91 nm and 68.9% 
entrapment 
efficiency  
Rats/ IV and 
IN drug 
solution  
The nanoparticles 
showed brain 
concentration 6.35-fold 
higher than the IV and 
10.86-fold higher than 
the IN delivery of the 
drug solution after 3 h 
[228] 
Lorazepam  Brain  BNP PLGA and 
Poloxamer 407 
153.7 nm and 83.8% 
drug entrapment 
Rats/ IV and 
IN free drug 
solution  
Lorazepam-PLGA-
loaded NPs showed 
higher brain/blood ratios 
at all sampling time 
points compared to the 
delivery of the drug 
solution 
[229] 
Rotigotine Brain  BNP PEG, PLGA, and 
Lactoferrin 
122 nm and 19% 
conjugation 
efficiency  
 
Rats/ IN NPs-
PLGA 
The modified nontoxic 
NPs showed 
heterogeneous brain 
distributions and higher 
targeting than the 
unconjugated NPs 
[230] 
NT-I Brain  BNP PLA and sodium 
cholate 
65 nm and 35.5% 
entrapment 
efficiency  
Rats/ IV NPs-
PLGA and IV 
of NT-I 
PLA-NPs of NT-I 
displayed lower brain 
Tmax and higher Cmax. The 
AUC0–4h values of IV-NP 
and IN-NP were 196% 
and 160%, respectively  
[231] 
Didanosin
e 
Brain  BNP Chitosan and TPP 269-382 nm, 9.1, and 
47.3% 
loading efficacy and 
90.7, 94.6% 
encapsulation 
efficiency for 10 and 
50% didanosine 
theoretical loading, 
respectively  
Rats/ IV and 
IN solution  
The NPs had CNS/ 
systemic distributions of 
1.9, 2.5-3.3, and 8.1-8.9 
for the brain, olfactory 
bulb and CSF, 
respectively. The NPs 
also showed 70.9% and 
38.9% bioavailability 
compared to the IV and 
IN delivery of the drug 
solution, respectively 
[232] 
Carboplati
n 
Brain  BNP PCL and PVA 311.6 nm and 
27.95% entrapment 
efficiency 
Rats/ In situ 
nasal solution  
In situ nasal studies 
demonstrated better nasal 
absorption for carboplatin 
from the NPs than the 
drug solution 
[233] 
Piperine Brain  BNP Chitosan, TPP, and 
Poloxamer 188 
248.5 nm and 81.7% 
encapsulation 
efficiency  
Rats/ IP 
donepezil 
pure drug and 
blank NPs 
Significant cognitive 
function improvement as 
with donepezil with the 
antioxidant and acetyl 
choline esterase inhibitor  
[234] 
bFGF Brain BNP  STL, PEG, and 
PLGA 
118.7 nm, 69.21% 
encapsulation and 
0.0462% loading 
efficiency  
Rats/ IV and 
IN- bFGF 
The conjugated NPs 
showed 1.79–5.17 and 
0.61–2.21-fold higher 
brain concentrations than 
the IV and IN delivery of 
the unmodified NPs, 
respectively. The 
modified solution also 
demonstrated an 
[235] 
improved cognitive 
function 
Rasagiline Brain  BNP Chitosan glutamate 
and TPP 
151.1  nm and 
96.43% 
encapsulation 
efficiency  
Mice/ IV and 
IN rasagiline  
The rasagiline NP had 2.8 
and 1.7 higher brain 
concentrations than the 
IV and IN, respectively. 
DTP was only 69.27% 
[236] 
Abbreviations: NP, nanoparticle; bFGF, Basic fibroblast growth fact; IP, intraperitoneal; CSF, cerebrospinal fluid; STL, Solanum 
tuberosum lectin; NT-I, Neurotoxin-I; PCL, polycaprolactone, PLA; polylactic acid. 
Biodegradable polymeric NPs are mainly based on chitosan and PLGA polymers. Their particle sizes are mostly in the range of 
50-400 nm with high encapsulation efficiency. Moreover, modifications of the nanoparticles are common procedures and 
mainly applied by PEG and other materials, such as PLA and Poloxamer. These modifications are useful in achieving the 
delivery goals that have been determined. 
4.4 Topicalities of Intranasal Nanoparticles on the Pharmaceutical Market 
In the last decades, intranasal products for systemic delivery have been marketed successfully. Examples of such products are 
zolmatriptan (Zomig®, Impax Laboratories Inc, USA) and sumatriptan (Imigran®, GlaxoSmithKline, UK) for treatment of 
migraine, fentanyl (PecFent®, Kyowa Kirin Services Ltd, Japan) for treatment of breakthrough pain in cancer and nicotine 
(Nicorette®, McNeil AB, Sweden) for smoking cessation. Moreover, various nasal peptide products are currently on the market, 
such as calcitonin (Miacalcin, Novartis®, USA) desmopressin (Desmospray®, Ferring, UK), buserelin (Suprecur®, Sanofi-
Aventis, UK) and nafarelin (Synarel®, Pfizer Service, Belgium) oxytocin. On the other hand, an influenza virus vaccine has 
been introduced (Flumist®, Medimmune, USA). 
 
Despite the significant research efforts in the nanoparticles field, there is still no FDA approved nanoparticle-based product for 
intranasal delivery. Nanoparticulate systems for nasal delivery represent a relatively new approach. Despite the unavailable data 
from company pipelines about the clinical trial and development of these products, BlueWillow Biologics, Inc. showed some 
clinical trials for NEs as vaccines (Table 6). Research in this area should be continued at an even higher pace to investigate the 
possibilities of introducing nanotechnology as a delivery system via the nasal route for different targets. 
Table 6. Examples of intranasal NEs for clinical consideration. 
Target Status 
Seasonal influenza  Phase1 
Pandemic influenza Preclinical 
RSV Preclinical  
Anthrax   Preclinical  
Pertussis  Preclinical 
HSV-2 Preclinical 
Chlamydia Preclinical 
Abbreviation: RSV, respiratory syncytial virus 
 
5. REGULATORY ASPECTS AND PATIENT EXPECTATIONS OF NASAL DELIVERY 
5.1 Regulatory Aspects and QbD Implementation in Nasal Dosage Form Developments 
Prior to the development of intranasal formulations (similarly to other administration routes as well), the objectives, materials, 
methods, delivery systems, and expected outcomes should be identified clearly to end up with a product that can compromise 
between patients’ demands and industrial expectation alongside with the regulatory guidelines of the FDA or EMA [237–239]. 
In 2005, the FDA enforced the submission of QbD with new drug application requests. The QbD approach provides a holistic 
view that can help in understanding and controlling the variables from the material selection to the scale up and 
commercialization of a medicinal product. Such designs offer the rewards of transferring the chemistry manufacturing control 
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(CMC) of the new abbreviated drug into the pharmaceutical quality assessment, thus saving the time of development and 
submission, saving the time of regulatory authorities’ approval, and defining the probability of out of specification and out of 
tolerance [240]. 
To implement QbD methodology, the quality target product profile (QTPP) must be defined initially. QTPP describes the 
profile of the drug delivery that is aimed to be reached; this will give the framework for the further adjustments during the 
development process. QbD-based development, later on, identifies the relations of the critical quality of attributes (CQAs), 
critical material attributes (CMA), and critical process parameters (CPP) with the product properties and control strategy 
according to ICH guidelines Q8, Q9, and Q10 to assess the product quality by referring to its efficacy and safety. For QbD, it is 
essential to apply a risk assessment and evaluation of the effects of the variables on production or the effects of the materials on 
safety and stability, thus it can help in the determination of the CQA and CMA, which highly affect the quality of the final 
product. 
The application of QbD for intranasal nanoparticles has been introduced by Pallagi et al [241]. This study pointed out the 
importance of the risk assessment-based QbD on the early stage production of intranasal meloxicam nanosuspension by co-
grinding with PVP-C30 stabilizer. The application of QbD provided an indication about the effects of parameters on the 
product quality, thus the researchers prioritized the study for the parameters of the greatest influence. Accordingly, the 
investigations revealed the importance of CPP (grinding time, rotation speed and meloxicam: PVP-C30 ratio) on CQA, 
particularly, particle size and dissolution rate. The optimization of 2 h grinding time, 400 rpm rotation speed and 1:1 
meloxicam: PVP-C30 was able to produce a nanosized product with 140 nm particle size and showed approximately 100% 
dissolution rate in the first 15 min. The nanosized product was formulated into nasal hydrogel with sodium hyaluronate and it 
showed Cmax at 5 min. Shah et al also applied the QbD approach for optimization rivastigmine SLN using homogenization and 
ultrasonication method. In this study, the authors set low particle size, low particle size distribution and high entrapment 
efficiency as CQAs. The effects of independent variables (drug: lipid ratio, surfactant concentration and homogenization time) 
on the previously determined CQAs were evaluated and a space design was built to determine the optimized formulation. The 
optimized formulation showed 82.5 particle size, 0.132 polydispersity index and 66.8% entrapment efficiency, also it showed 
65.9% ex vivo diffusion compared to 32.8% for the drug’s solution. In another study, Shah et al reported the use of QbD and 
risk assessment and optimization of venlafaxine-loaded nanostructured lipid carrier. QbD was built and the CQAs were 
identified. From the design space, the optimized formulation was characterized by a particle size of 77 nm, a particle size 
distribution of 0.234 and 81.3 % entrapment efficiency. Moreover, it displayed a higher diffusion rate of 14.2 mg/cm2/h through 
nasal mucosa in comparison to 9.62 mg/cm2/h for the solution [188,242]. 
In accordance with intranasal literature, QbDs have been applied mainly to the formulations rather than the final product. 
Chudiwal et al reported the development of budesonide suspension nasal spray with QbD as a case study. In this study, the 
delivery device variables were recognized alongside the material and process variables [243].  
Nanoparticles can be formulated into different dosage forms, such as liquids, gels, sprays, aerosols, and powders. The selection 
of the dosage forms depends on the drug type and formulation properties, the required effects and the targeted patient 
population. All traditional and new olfactory region targeted technologies, such as bidirectional (Optinose)®, Controlled 
Particle Dispersion (CPD)® (Kurve), and Pressurized Olfactory Device (POD) can widen and specify the intranasal delivery for 
efficient outcomes [244,245].  
Paying attention to the delivery system to meet the challenges of proper deposition and nasal cavity geometrical barriers is 
highly required. All technological parameters such as plume geometry and applied force directly affect the deposition of drugs; 
whereas, particle size has massive effects on the deposition as large particles tend to deposit in the anterior part without deep 
penetration. 
The used delivery system must meet the FDA and EMA guidance requirements for nasal formulations, especially related to 
reproducibility and dose uniformity, besides the efficiency for delivering the formulation into the suitable regions. Such 
guidance offers great management for the quality aspects of nasal products and clarifies the requirements for regulations and 
the industry [237,246]. 
Fig. (2) represents the Ishikawa diagram. It shows the most important CPP and CMP, and the factors affecting drug products; 
whereas Fig. (3) shows the general flow chart for designing intranasal formulations. One can conclude from the complexity of 
the job (nanotechnology-based intranasal formulation), as illustrated in the figures, that a careful selection of the composition 
and the preparation method should be performed together with an initial risk assessment in order to directly get a product with 
the required quality parameters. 
 
Fig. (2). Ishikawa diagram illustrating the parameters influencing the quality of an intranasal nanoparticulate system. 
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Fig. (3). General method development strategy for intranasal nanoparticulates. 
5.2 Evaluation of Patients’ Expectations of Intranasal Delivery 
Patients -as users of the medicinal products- have an increasing role in therapeutic success. Identifying what is expected or is 
critical for patients and reflecting these aspects during research and development is the first step to achieve patient acceptance 
and the required therapeutic outcome. This field has been ignored for many years, but as the effects of customers’ preferences 
increase, it should be considered more as part of R&D thinking [247–249]. 
Patient requirements have extended the need for safe and efficient drug delivery to other concerns such as the comfort of both 
formulation and applicator device in the nasal cavity, the ease of application, confidence in the delivered amount, and a warning 
about the remaining dose (dose counting). All these factors can enhance patients’ satisfaction and, therefore, their adherence 
[250,251]. In order to improve efficiency and productivity, manufacturers must understand the best tools, methods, and 
analysis. They have to define their goals on the basis of the patients’ voices before proceeding into the production stage. 
Integrating the voice of the customer can help to assess the patients’ convenience for their product and induce manufacturers to 
develop patient-friendly products. These considerations have not been kept in the theoretical framework or companies, but have 
transferred to the regulatory agencies that seriously consider patients’ preferences and their assessments of using formulations 
and delivery devices [252]. 
6. EXPERT OPINION 
The successful delivery of intranasal nanoformulations depends on many mutually dependent parameters: the selection of the 
nanotechnology method that can provide accepted encapsulation capacity and protection, the active pharmaceutical agent, the 
nanoparticulate system and the formulation properties, and the proper delivery system for the intended purposes. It is not an 
easy task to compromise between all aspects. Whilst various successful nanotechnology-based formulations have reached the 
market, intranasal products are still not available. Based on the previous literature and market research works, most marketed 
nasal products are available as nasal sprays and aerosols for local delivery, whilst the number of systemic and brain targeting 
products is lower and only one nasal vaccine is available.  
The utilization of nanotechnology in intranasal delivery has shown promising results. The majority of the studies has focused 
on the efficiency of the delivery and how to modify the system to achieve acceptable outcomes, whilst the potential toxicity of 
these systems has not been adequately revealed. Lipid-based systems represent a high percentage of the studies. On the other 
hand, polymeric nanoparticles have focused mainly on chitosan, PLGA, and their modifications. Although the marketed 
products and patents for nanotechnology-based products are low, nanoemulsion adjuvant vaccines are under different clinical 
trials. 
Nanoparticles/ nanocrystals have shown effective systemic, brain targeting, and vaccine delivery. However, it is not yet fully 
figured out if nanoparticles/ nanocrystals enhance delivery due to their design properties or due to their effects on residence 
time enhancement or/ and protection of the encapsulated agents against enzymatic degradation and the pg-efflux system.  
The proper selection of the best system should not be separated from the final goal of providing a product combined for 
efficiency, safety, stability, and patient acceptance for acute and chronic use. Due to complexity, the implementation of QbD 
can offer a tool for early-stage assessment for constituents, methods, and delivery system selection in addition to the possibility 
of risk assessment before drug development. It is highly recommended to be adopted.  
7. CONCLUSION AND PROSPECTIVE FUTURE 
Intranasal delivery has shown the possibility of being a simple and direct method that can replace many traditional routes. Local 
delivery offers higher efficiency and lower side effects, systemic targeting can improve the bioavailability of many agents and 
nasal vaccination produces rapid mucosal and systemic immunity that has not been achieved by the parenteral route. 
Nanoparticles showed the advantages of drug protection, enhancement of contact time, enhancement of drug solubility, ability 
of being easily functionalized and using of GRAS excipient. Therefore, they have the potential to overcome the traditional 
limitation of the nasal delivery. The suitability of intranasal nanoparticles for brain targeting and bypassing the blood brain 
barrier has demonstrated a way for treatment of unresolved CNS conditions and opened a new scope for treatment of aggressive 
brain tumors either by drugs or vaccine delivery. The intranasal administration of nanoparticles for a systemic effect showed 
effective results with regard to bioavailability, plasma maximum concentration, and time to reach the maximum concentration. 
Moreover, different studies on nanoparticle-based vaccines displayed the ability of these systems to elicit mucosal and systemic 
immune responses with adjuvant activity.  
The successful formulations can map the future of intranasal delivery. However, there are still many challenges to face. 
Increasing knowledge of nanotechnology is the first step towards successful delivery. The two-branch approach of utilizing 
nanoparticles coupled with intranasal delivery can provide the opportunities for efficient and convenient drug (vaccine) 
delivery. Accordingly, the future decades will most likely witness the production of intranasal formulations that overcome the 
current limitations. 
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